Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LENZ Therapeutics

交易中 08-17 11:25:00 EDT

4.68

-0.05

-1.06%

最高4.82	最低4.65	成交量17.65万
今开4.71	昨收4.73	日振幅3.59%
总市值1.46亿	流通市值7,930万	总股本3,129万
成交额83.30万	换手率1.04%	流通股本1,694万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":4.68,"timestamp":1786980300036,"preClose":4.73,"halted":0,"volume":176504,"delay":0,"changeRate":-0.010570824524313046,"floatShares":16943600,"shares":31289969,"eps":-4.13,"marketStatus":"交易中","change":-0.05,"latestTime":"08-17 11:25:00 EDT","open":4.71,"high":4.82,"low":4.65,"amount":832965.61948,"amplitude":0.035941,"askPrice":4.69,"askSize":324,"bidPrice":4.67,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1786996800000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":4.73,"preHourTrading":{"tag":"盘前","latestPrice":4.72,"preClose":4.73,"latestTime":"09:28 EDT","volume":733,"amount":3541.656624,"timestamp":1786973299030,"change":-0.01,"changeRate":-0.002114,"amplitude":0.031712},"postHourTrading":{"tag":"盘后","latestPrice":4.85,"preClose":4.73,"latestTime":"19:53 EDT","volume":3625,"amount":17237.185,"timestamp":1786751621848,"change":0.12,"changeRate":0.02537,"amplitude":0.02537},"volumeRatio":0.566098,"impliedVol":3.6161,"impliedVolPercentile":0.9841},"requestUrl":"/m/hq/s/LENZ","defaultTab":"news","newsList":[{"id":"1164486796","title":"Lenz Therapeutics遭美银全球研究下调评级：从“买入”降至“中性”，目标价从31美元大幅下调至7美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164486796","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164486796?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:10","pubTimestamp":1786619414,"startTime":"0","endTime":"0","summary":"美银全球研究机构近日对Lenz Therapeutics作出了关键性调整。该机构将这家公司的股票评级从“买入”直接下调至“中性”。这并非孤立的举措，同一时间，它们还彻底修正了其价格预期，目标价已从先前的31美元大幅削减至7美元，降幅十分显著。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931704","title":"Tenax Therapeutics股价暴跌87.2%，此前该公司的心脏药物在后期研究中未达到主要目标。","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931704","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658931704?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:31","pubTimestamp":1786368718,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193258586","title":"新闻稿：Ernexa Therapeutics 引入资深生物技术高管 David Polinsky 加入董事会，为临床阶段冲刺蓄力","url":"https://stock-news.laohu8.com/highlight/detail?id=1193258586","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193258586?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:09","pubTimestamp":1786367399,"startTime":"0","endTime":"0","summary":"此次任命正值公司关键转折点，进一步强化了其领导团队——Ernexa 正全力推进其核心项目 ERNA-101，计划于2026年第三季度提交新药临床试验申请，并在第四季度启动首项一期临床研究。马萨诸塞州剑桥市，2026年8月10日——Ernexa Therapeutics，一家致力于开发创新细胞疗法以治疗晚期癌症和自身免疫性疾病的行业先锋，今日宣布任命 David Polinsky 为其董事会成员。“我们正步入 Ernexa 历史上最为重要的时期之一，”Ernexa Therapeutics 总裁兼首席执行官 Sanjeev Luther 表示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RFL","BK4233","BK4205","BBP","ERNA","IBB","BK4539","BK4139","BK4588","BK4585","LENZ","SYNB","XBI","BK4007","IND","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933459","title":"Axsome Therapeutics（AXSM）二季度GAAP每股盈亏为0.99美元 营业收入2.184亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933459","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658933459?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:27","pubTimestamp":1786361253,"startTime":"0","endTime":"0","summary":"金吾财讯 | Axsome Therapeutics 公布第二季度财务数据，公司GAAP每股盈亏为0.99美元，较市场预期低0.10美元。当期实现营业收入2.184亿美元，同比增幅达到45.6%，但较市场一致预期少338万美元。该企业专注于中枢神经系统领域药物开发与商业化，本季度营收大幅上涨，主要来源于已上市药物的市场销售放量。不过销售、研发等多项运营开支同步走高，最终造成每股亏损不及预期。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210625/YzM5OTgzZmE3NTA3Njg3Nzc4Mjg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM5OTgzZmE3NTA3Njg3Nzc4Mjg=.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303617","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","AXSM","UUP","UDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658938295","title":"SIONNA Therapeutics 公布主要终点更新数据后，盘前股价暴跌 87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658938295?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:13","pubTimestamp":1786360392,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657640905","title":"Blossomhill Therapeutics Inc.美国IPO首日开盘报15.75美元，此前给出的IPO发行价为每","url":"https://stock-news.laohu8.com/highlight/detail?id=2657640905","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657640905?lang=zh_cn&edition=full","pubTime":"2026-08-08 00:33","pubTimestamp":1786120437,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FRHC","REDS","LENZ","BK4127","BK4539","UUP","KCE","UDN","IPOS","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657640472","title":"美股异动 | BlossomHill Therapeutics(BLSM.US)登陆美股市场 开盘后股价小幅走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2657640472","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657640472?lang=zh_cn&edition=full","pubTime":"2026-08-08 00:00","pubTimestamp":1786118400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，BlossomHill Therapeutics登陆美股市场，截至发稿，该股跌超1%，报15.8美元。BlossomHill Therapeutics总部位于加州圣地亚哥，成立于2020年。该公司专注于通过识别现有治疗方法中的结构性弱点，并设计新的化合物来克服这些弱点，从而开发小分子癌症药物。公司计划于2026年第四季度与美国食品药品监督管理局举行一期临床结束会议，讨论推荐的二期临床给药方案，以及针对部分患者潜在的加速批准路径。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BLSM","BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193281325","title":"新闻稿：Rani Therapeutics 任命 Michelle Gilson 加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1193281325","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193281325?lang=zh_cn&edition=full","pubTime":"2026-08-04 20:12","pubTimestamp":1785845578,"startTime":"0","endTime":"0","summary":"加利福尼亚州圣何塞，2026年8月4日——专注于口服生物制剂递送的临床阶段生物治疗公司 Rani Therapeutics Holdings, Inc.今日宣布，任命 Michelle Gilson 为其董事会成员。Gilson 女士将担任审计委员会主席。“Michelle 兼具深厚的资本市场专业知识和在高增长生物技术公司担任财务领导的实际经验，这使她成为我们董事会的一位卓越新成员，”Rani Therapeutics 首席执行官 Talat Imran 表示。“能在公司如此关键的时期加入 Rani Therapeutics 董事会，我深感荣幸，”Michelle Gilson 说道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4022","BK4007","BK4232","BK4139","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656303576","title":"专注肿瘤领域的生物技术公司BlossomHill Therapeutics计划通过首次公开募股募资约1.328亿美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656303576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656303576?lang=zh_cn&edition=full","pubTime":"2026-08-04 00:41","pubTimestamp":1785775260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SPCK","BK4139","HELX","IPO","WDNA","ACSG","LENZ","LQPE","QQQS","PEVC","BK4007","BCSM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654885615","title":"生物科技公司Capricor Therapeutics面临FDA质疑与证券欺诈调查 股价连续暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2654885615","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654885615?lang=zh_cn&edition=full","pubTime":"2026-07-28 23:15","pubTimestamp":1785251700,"startTime":"0","endTime":"0","summary":"生物科技公司Capricor Therapeutics正面临严峻挑战，其股价近期大幅下挫——周一该股收盘重挫64.49%，周二早盘再跌逾15%。FDA审查人员对Capricor的核心候选药物deramiocel的疗效数据提出质疑，认为其关键性III期HOPE-3试验未能达到预设的主要和关键次要疗效终点。此外，多家律师事务所已对Capricor提起或正在调查证券欺诈集体诉讼。诉讼主要指控公司在2024年10月9日至2025年7月10日期间，就其获得FDA批准的可能性作出了虚假和误导性陈述，同时隐瞒了关于deramiocel安全性和有效性的不利事实。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-28/doc-inikksxz1845469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBJ","LABU","BK4581","GDOC","SYNB","BK4007","BK4585","BK4588","HBImain","LNGR","BK4539","IEIH","161027","BK4139","LENZ","159837","MEDX","AGNG","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654036699","title":"美股异动 | CRISPR基因编辑公司Scribe Therapeutics(SCTX.US)登陆美股市场 开盘后涨超59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654036699","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654036699?lang=zh_cn&edition=full","pubTime":"2026-07-24 23:57","pubTimestamp":1784908651,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1861559042.SGD","BK4139","XT","BK4585","NBDS","WDNA","DTEC","BK4556","BK4007","SYNB","BMED","LU1861558580.USD","ARKG","IDNA","FWD","TARK","SCTX","GNOM","BK4588","LENZ","BK4539","CRSP","BK4611","KOMP","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653751229","title":"Summit Therapeutics美股盘前跌超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653751229","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653751229?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:36","pubTimestamp":1784716593,"startTime":"0","endTime":"0","summary":"Summit Therapeutics美股盘前跌超11%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817433621.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817433621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652298740","title":"小分子抗癌疗法开发商BlossomHill Therapeutics(BLSM.US)申请美股上市 拟筹资至多1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652298740","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652298740?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:20","pubTimestamp":1784532012,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，BlossomHill Therapeutics是一家管线已推进至二期临床阶段的生物技术企业，专注于开发小分子抗癌疗法。该公司于上周五向美国证券交易委员会递交招股书，拟通过首次公开募股募资至多1亿美元。BlossomHill Therapeutics专注研发小分子抗癌药物：先找出现有疗法的结构缺陷，再设计新的化合物来克服这些缺陷。BlossomHill Therapeutics于2026年4月24日秘密提交了上市申请。摩根大通、Leerink Partners、Guggenheim Securities、LifeSci Capital和HC Wainwright是此次交易的联合承销商。定价条款未披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","BK4539","IPOS","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652298685","title":"缺氧疗法生物科技公司NuvOx Therapeutics(NUOX.US)申请美股IPO，拟募资2000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652298685","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652298685?lang=zh_cn&edition=full","pubTime":"2026-07-20 14:55","pubTimestamp":1784530507,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AGNG","FRHC","KCE","LENZ","SYNB","BK4588","BK4539","MEDX","GDOC","BK4585","XBI","BK4127","BK4007","BK4139","BK4581","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182696709","title":"新闻稿：Glucotrack与Lōkahi Therapeutics完成战略业务合并，建立Lōkahi控制的公开平台","url":"https://stock-news.laohu8.com/highlight/detail?id=1182696709","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182696709?lang=zh_cn&edition=full","pubTime":"2026-07-15 05:45","pubTimestamp":1784065528,"startTime":"0","endTime":"0","summary":"Glucotrack, Inc.今日宣布，其与Lōkahi Therapeutics的战略业务合并已正式完成。本次交易的结构设计使得Lōkahi Therapeutics成为合并后公司的运营及控制主体，并利用Glucotrack的公开市场平台来支持长期增长及资本获取。在交易完成之际，Lōkahi Therapeutics的证券持有人获得了Glucotrack普通股与可转换优先股的组合。届时，在完全稀释基础上，并受交易相关融资及常规调整影响，Lōkahi Therapeutics的证券持有人将持有合并后公司约90%的股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GCTK","LENZ","BK4082","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651174232","title":"信达生物与 Spero Therapeutics就IBI355（第三代抗CD40L单抗，临床II期准备阶段）达成独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2651174232","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651174232?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:00","pubTimestamp":1784023200,"startTime":"0","endTime":"0","summary":"Spero计划于2027年第二季度启动IBI355治疗IgG4-RD患者的临床II期研究；信达生物计划于2027年初前在中国启动IBI355治疗SjD的临床II期研究。我们非常高兴与Spero Therapeutics达成合作，共同推进IBI355的全球开发。结合信达生物和Spero Therapeutics在自身免疫领域的临床资源和专注投入，我们将共同加速这一差异化疗法的研发进程，致力于为慢性病患者带来新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5003988_ZH03988_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5003988_ZH03988_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01801","BK4539","LU2488822045.USD","LU2097828474.EUR","LU2242644610.SGD","KURE","BK1161","BK1589","BK1583","LU2097828557.USD","LU2097828714.EUR","LU2097828805.USD","BK4007","LU1969619763.USD","LU0502904849.HKD","LU0455707207.USD","HK0000165453.HKD","BK4139","LU2097828631.EUR","LU2328871848.SGD","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651722111","title":"Stoke Therapeutics任命Thomas McCauley博士为首席科学官","url":"https://stock-news.laohu8.com/highlight/detail?id=2651722111","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651722111?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:49","pubTimestamp":1783946940,"startTime":"0","endTime":"0","summary":"生物技术公司Stoke Therapeutics近日宣布，任命Thomas McCauley博士为首席科学官，负责领导公司的科学战略，并推动其基于RNA药物平台的管线扩展与临床推进。他曾担任Neptune Bio的总裁兼首席执行官，并先后在Omega Therapeutics、Macrolide Pharmaceuticals和Translate Bio担任首席科学官。　　Stoke Therapeutics专注于利用其专有的TANGO技术开发反义寡核苷酸药物，以选择性恢复蛋白质水平。Stoke与渤健已就此药物建立战略合作，共同进行开发和商业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-13/doc-inihsisy8947593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183275253","title":"Pliant Therapeutics任命Flavia Borellini博士和Robert Iannone博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1183275253","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183275253?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:35","pubTimestamp":1783946106,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司Pliant Therapeutics今日宣布，任命Flavia Borellini博士与Robert Iannone博士为公司董事会新成员。这两项任命为董事会注入了深厚的全球肿瘤药物开发经验，并进一步强化了其在运营与监管事务方面的专业能力。目前，除了在Pliant任职外，他还担任Autolus Therapeutics的董事会成员。关于Pliant Therapeutics, Inc.：Pliant Therapeutics是一家临床阶段的生物制药公司，专注于基于整合素的疗法的发现与开发。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","BK4007","BK4139","BK4585","LENZ","R","BK4588","BK4022","BK4539","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650924739","title":"Cardiol Therapeutics将出席B. Riley Mind, Muscle & Vision峰会炉边谈话","url":"https://stock-news.laohu8.com/highlight/detail?id=2650924739","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650924739?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:54","pubTimestamp":1783601672,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics Inc．宣布，将参加于2026年7月16日在波士顿举行的B． Riley Securities Mind， Muscle & Vision Summit，并在当日下午12：20进行炉边谈话。　　此次峰会为B． Riley Securities主办的单一医疗健康会议，聚焦神经学、肌肉及眼科疾病领域的创新成果。　　Cardiol Therapeutics是一家处于后期阶段的生命科学公司，专注于推进心脏疾病抗炎和抗纤维化疗法的开发。　　Cardiol目前正在推进MAVERIC项目，评估CardiolRx治疗复发性心包炎的疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-09/doc-inihfihx8573744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649858622","title":"Incyte(INCY)以12.5亿美元完成收购Vega Therapeutics 拓宽血液学管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2649858622","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649858622?lang=zh_cn&edition=full","pubTime":"2026-07-06 21:19","pubTimestamp":1783343950,"startTime":"0","endTime":"0","summary":"根据双方此前达成的股票购买协议，Incyte已支付12.5亿美元的预付款，收购了Vega Therapeutics的全部发行在外股份。此外，Star Therapeutics未来还有权获得最高达7.5亿美元的商业销售里程碑付款。通过本次收购，Incyte成功将Vega的核心资产——创新单克隆抗体VGA039收入囊中。目前，该药物正在全球开展一项名为VIVID-6的单臂交叉3期临床试验，以评估其在各类血管性血友病患者中的安全性和有效性。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302236","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LENZ","INCY","BK4550","BK4539","BK4588","BK4139","IDNA","BK4532","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.1175},{"period":"1month","weight":-0.0521},{"period":"3month","weight":-0.3556},{"period":"6month","weight":-0.6328},{"period":"1year","weight":-0.8844},{"period":"ytd","weight":-0.7044}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LENZ Therapeutics, Inc.最初于2017年6月1日在加拿大安大略省注册成立，随后于2019年10月在特拉华州重新注册成立。该公司是一家商业制药公司，专注于开发和商业化改善视力的疗法，其主导产品VIZZ被批准用于治疗老花眼。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":-0.009929},{"month":7,"riseRate":0.5,"avgChangeRate":0.033083},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.004145},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}